Q3 Highlights: ICON entered a multi-year collaboration with Anthropic to build Claude into its Orbis platform, Samsung Biologics launched a $1.8B tender offer for peptide CDMO PolyPeptide group, and Tempus AI agreed to acquire MRD-testing company Personalis to expand its precision oncology platform.

‍

‍

Digital Transformation & AI

Syneos Health Deepens Its AI Ecosystem Across Clinical Development

Syneos Health expanded its enterprise AI ecosystem with a new collaboration with Causaly for agentic, evidence-based scientific reasoning (cutting study-strategy research time by roughly half) alongside deepened use of Databricks and Microsoft 365 Copilot to speed protocol design, feasibility, and trial monitoring.

Charles River Pathway Purpose Strategy Emphasizes Digital Enablement

At its 2026 Investor Day, Charles River unveiled its "Pathway to Purpose" strategy, with one of its three pillars, modernizing the company, centered on its "Create the Future" program: expanding AI-assisted digital tools, automation, and digitization to simplify operations, cut drug development timelines, and boost client satisfaction. They have a target of over $300M in cumulative savings from 2027–2030 through the program.  

ICON Partners with Anthropic to Deploy Claude Across Clinical Trials

ICON entered a multi-year collaboration with Anthropic to build four AI capabilities into its Orbis platform (including site selection, enrollment-risk detection, protocol optimization, and client-facing insight tools), with Claude rolled out across its developer, knowledge, and clinical teams.

‍

High Value Licensing

Shilpa Biologicals Expands CDMO Role With Orion Nivolumab Biosimilar DealShilpa Biologicals, an India-based CDMO, signed a co-development and supply deal with Orion Corporation to become the exclusive long-term manufacturer of an EU-GMP nivolumab biosimilar, extending its biologics manufacturing footprint into immuno-oncology.

‍

‍

CAP-EX

Evotec Names Rui Wang as EVP, Head of Global In Silico and AI

Evotec appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI. The role will shape and execute global strategy for AI-driven, in silico innovation. Rui Wang recently served as the Head of Data, Analytics and AI at AstraZeneca.  

Almac Becomes Olink Certified Service Provider for Proteomics

Almac expanded its proteomics service offering for biopharma clients, becoming a certified provider for Olink's targeted protein biomarker platform.

‍

M&A

Samsung Biologics Makes Its Largest-Ever Acquisition With $1.8B PolyPeptide Bid  

Samsung Biologics launched an all-cash tender offer for Swiss peptide CDMO PolyPeptide Group, marking South Korea's largest-ever biopharma takeover and giving Samsung entry into peptide manufacturing for the booming GLP-1/obesity market.

Tempus AI to Acquire Personalis, Deepening Its Cancer-Monitoring Platform  

Tempus AI agreed to acquire molecular residual disease (MRD) testing company Personalis, aiming to fold Personalis' cancer-monitoring technology into Tempus' AI-driven precision oncology platform and broaden its reach across the cancer care continuum.

Fortrea Acquires Worldwide Clinical Trials' Early Phase Services Division for $45M
Fortrea agreed to acquire Worldwide Clinical Trials' Early Phase Services division, including a GLP bioanalytical lab in Austin and a 200-bed clinical pharmacology unit in San Antonio, to strengthen its early-phase development platform, while Worldwide refocuses on its faster-growing late-stage oncology, neuroscience, and rare disease business.